BIOMARKER:

RNF43 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

RNF43 mutation	Colorectal Cancer	RNF43 mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
RNF43 mutation	Colorectal Cancer	RNF43 mutation	Colorectal Cancer	encorafenib Sensitive: C3 – Early Trials encorafenib Sensitive : C3	encorafenib Sensitive: C3 – Early Trials encorafenib Sensitive : C3
RNF43 mutation	Colorectal Cancer	RNF43 mutation	Colorectal Cancer	cetuximab + alpelisib + encorafenib Sensitive: C3 – Early Trials cetuximab + alpelisib + encorafenib Sensitive : C3	cetuximab + alpelisib + encorafenib Sensitive: C3 – Early Trials cetuximab + alpelisib + encorafenib Sensitive : C3
RNF43 mutation	Bladder Cancer	RNF43 mutation	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
RNF43 mutation	Pancreatic Ductal Adenocarcinoma	RNF43 mutation	Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials avelumab + binimetinib Sensitive : C3	avelumab + binimetinib Sensitive: C3 – Early Trials avelumab + binimetinib Sensitive : C3
RNF43 mutation	Colorectal Cancer	RNF43 mutation	Colorectal Cancer	PORCN inhibitor Sensitive: D – Preclinical PORCN inhibitor Sensitive : D	PORCN inhibitor Sensitive: D – Preclinical PORCN inhibitor Sensitive : D